{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T01:37:14Z","timestamp":1792287434911,"version":"4.4.0"},"reference-count":27,"publisher":"Bentham Science Publishers Ltd.","issue":"3","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec>\n<jats:title>Aims:<\/jats:title>\n<jats:p>This study aims to comprehensively investigate the role of Family Member A\nwith sequence similarity 72-A (FAM72A) in multiple myeloma.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Multiple myeloma poses significant challenges. This study delves into FAM72A's\nimpact on key cellular processes, shedding light on potential therapeutic targets and enhancing\nour understanding of multiple myeloma progression.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objective:<\/jats:title>\n<jats:p>Investigate the impact of FAM72A on the proliferation, apoptosis, and bortezomib\nsensitivity of multiple myeloma cell line U266.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>qRT-PCR analyzed FAM72A expression levels in bone marrow samples from 30 patients\nwith multiple myeloma and 10 healthy donors at the Second Hospital of Shanxi Medical\nUniversity. Cell lines overexpressing FAM72A were constructed, and Cell Counting Kit 8\n(CCK-8) and flow cytometry were used to assess U266 cell proliferation, apoptosis, and sensitivity\nto bortezomib. Biological predictions for FAM72A were performed to find transcription factors\nbinding to the FAM72A promoter region, verified using a luciferase assay. U266 cells were\ntransfected with si-POU2F2 (POU class 2 homeobox 2), and the impact on cell proliferation was\nvalidated. Western blot analysis detected the expression of downstream proteins in the p53 signaling\npathway. In vivo, experiments established a xenograft mouse model further to study the\nrole of FAM72A in multiple myeloma.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>FAM72A was upregulated in multiple myeloma bone marrow tissues. Compared to the\nOE-NC group, the OE-FAM72A group showed increased Mouse Double Minute 2 homolog\n(MDM2) expression, decreased p53 expression, increased cell proliferation, and decreased apoptosis.\nPOU2F2 was identified as the upstream transcription factor for FAM72A. Compared to the\nsi-NC group, the si-POU2F2 group exhibited decreased MDM2 expression, increased p53 expression,\nslowed cell proliferation, and increased apoptosis. Silencing POU2F2 could reverse the\npro-proliferative effect of over-expressing FAM72A in U266 cells. In vivo experiments in a xenograft\nmouse model further studied the role of FAM72A in multiple myeloma.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Overexpression of FAM72A promotes U266 cell proliferation, inhibits apoptosis,\nand reduces sensitivity to bortezomib by regulating the POU2F2\/FAM72A\/p53 signaling pathway.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0113892010311258240729080309","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T06:06:38Z","timestamp":1723442798000},"page":"455-464","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Expression and Function of FAM72A Gene in Multiple MyelomaFAM72A"],"prefix":"10.2174","volume":"26","author":[{"given":"Wenyu","family":"Gao","sequence":"first","affiliation":[{"name":"Second Clinical Medical College, Shanxi Medical University, No.56, Xinjian South Road, Taiyuan City, Shanxi\nProvince, 030000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Ma","sequence":"additional","affiliation":[{"name":"Second Clinical Medical College, Shanxi Medical University, No.56, Xinjian South Road, Taiyuan City, Shanxi\nProvince, 030000, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"102284","DOI":"10.1016\/j.ctrv.2021.102284","volume":"100","author":"Rodriguez-Otero P.","year":"2021","unstructured":"Rodriguez-Otero P.; Paiva B.; San-Miguel J.F.; Roadmap to cure multiple myeloma. Cancer Treat Rev  2021,100,102284","journal-title":"Cancer Treat Rev"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s13045-020-00962-7","volume":"13","author":"Yu B.","year":"2020","unstructured":"Yu B.; Jiang T.; Liu D.; BCMA-targeted immunotherapy for multiple myeloma. J Hematol Oncol  2020,13(1),125","journal-title":"J Hematol Oncol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1182\/blood.2022018461","volume":"141","author":"Lagan\u00e0 A.","year":"2023","unstructured":"Lagan\u00e0 A.; The genome of IMiD-refractory myeloma. Blood  2023,141(6),560-561","journal-title":"Blood"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s40170-017-0169-9","volume":"5","author":"Zaal E.A.","year":"2017","unstructured":"Zaal E.A.; Wu W.; Jansen G.; Zweegman S.; Cloos J.; Berkers C.R.; Bortezomib resistance in multiple myeloma is associated with increased serine synthesis. Cancer Metab  2017,5(1),7","journal-title":"Cancer Metab"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1042\/BST20140126","volume":"42","author":"Murray M.Y.","year":"2014","unstructured":"Murray M.Y.; Auger M.J.; Bowles K.M.; Overcoming bortezomib resistance in multiple myeloma. Biochem Soc Trans  2014,42(4),804-808","journal-title":"Biochem Soc Trans"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1515\/hsz-2017-0190","volume":"399","author":"Ho N.T.T.","year":"2017","unstructured":"Ho N.T.T.; Kutzner A.; Heese K.; Brain plasticity, cognitive functions and neural stem cells: a pivotal role for the brain-specific neural master gene |-SRGAP2\u2013FAM72-|. Biol Chem  2017,399(1),55-61","journal-title":"Biol Chem"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"105695","DOI":"10.1016\/j.archoralbio.2023.105695","volume":"151","author":"Liu H.","year":"2023","unstructured":"Liu H.; Huang Y.; Chen Y.; Tang Z.; Huang M.; Ming Y.; Wang M.; Chen W.; Huang Z.; Qing L.; Wang Q.; Jia B.; Family with Sequence Similarity 72 (FAM72) \u2212 A prospective biomarker for poor prognosis in patients with oral squamous cell carcinoma. Arch Oral Biol  2023,151,105695","journal-title":"Arch Oral Biol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1046473","DOI":"10.3389\/fonc.2022.1046473","volume":"12","author":"Zhou Q.","year":"2022","unstructured":"Zhou Q.; Chen L.; Yang L.; Zhou H.; Chen Y.; Guo Y.; Integrated systemic analysis of FAM72A to identify its clinical relevance, biological function, and relationship to drug sensitivity in hepatocellular carcinoma. Front Oncol  2022,12,1046473","journal-title":"Front Oncol"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"6118","DOI":"10.1158\/0008-5472.CAN-08-1259","volume":"68","author":"Guo C.","year":"2008","unstructured":"Guo C.; Zhang X.; Fink S.P.; Platzer P.; Wilson K.; Willson J.K.V.; Wang Z.; Markowitz S.D.; Ugene, a newly identified protein that is commonly overexpressed in cancer and binds uracil DNA glycosylase. Cancer Res  2008,68(15),6118-6126","journal-title":"Cancer Res"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/tox.23751","volume":"38","author":"Xu Y.","year":"2023","unstructured":"Xu Y.; Hirachan S.; Shen Y.; Huang Q.; Bhandari A.; Xia E.; The pan\u2010cancer analysis of the oncogenic role of FAM72A as a BRCA prognostic biomarker and immunotherapeutic target. Environ Toxicol  2023,38(5),1100-1117","journal-title":"Environ Toxicol"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"903","DOI":"10.7150\/jca.82949","volume":"14","author":"Zeng Y.","year":"2023","unstructured":"Zeng Y.; Xiong C.; Tang N.; Wang S.; Xiong Z.; Liang T.; Wang Q.; Li M.; Li J.; FAM72A promotes glioma progression by regulating mitophagy through the Pink1\/Parkin signaling pathway. J Cancer  2023,14(6),903-915","journal-title":"J Cancer"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/j.devcel.2023.02.006","volume":"58","author":"Fu Y.","year":"2023","unstructured":"Fu Y.; Jia X.; Yuan J.; Yang Y.; Zhang T.; Yu Q.; Fam72a functions as a cell-cycle-controlled gene during proliferation and antagonizes apoptosis through reprogramming PP2A substrates. Developmental Cell  2023,58(5),398-415","journal-title":"Developmental Cell"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3390\/cancers13020217","volume":"13","author":"Garc\u00eda-Ortiz A.","year":"2021","unstructured":"Garc\u00eda-Ortiz A.; Rodr\u00edguez-Garc\u00eda Y.; Encinas J.; Maroto-Mart\u00edn E.; Castellano E.; Teixid\u00f3 J.; Mart\u00ednez-L\u00f3pez J.; The role of tumor microenvironment in multiple myeloma development and progression. Cancers  2021,13(2),217","journal-title":"Cancers"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"3793","DOI":"10.1158\/1078-0432.CCR-20-2188","volume":"27","author":"Holthof L.C.","year":"2021","unstructured":"Holthof L.C.; van der Schans J.J.; Katsarou A.; Poels R.; Gelderloos A.T.; Drent E.; van Hal-van Veen S.E.; Li F.; Zweegman S.; van de Donk N.W.C.J.; Themeli M.; Groen R.W.J.; Mutis T.; Bone marrow mesenchymal stromal cells can render multiple myeloma cells resistant to cytotoxic machinery of CAR T cells through inhibition of apoptosis. Clin Cancer Res  2021,27(13),3793-3803","journal-title":"Clin Cancer Res"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"101506","DOI":"10.1016\/j.bbrep.2023.101506","volume":"35","author":"Gou H.","year":"2023","unstructured":"Gou H.; Chen P.; Wu W.; FAM72 family proteins as poor prognostic markers in clear cell renal carcinoma. Biochem Biophys Rep  2023,35,101506","journal-title":"Biochem Biophys Rep"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"774","DOI":"10.3324\/haematol.2019.222133","volume":"105","author":"Chatonnet F.","year":"2020","unstructured":"Chatonnet F.; Pignarre A.; S\u00e9randour A.A.; Caron G.; Avner S.; Robert N.; Kassambara A.; Laurent A.; Bizot M.; Agirre X.; Prosper F.; Martin-Subero J.I.; Moreaux J.; Fest T.; Salbert G.; The hydroxymethylome of multiple myeloma identifies FAM72D as a 1q21 marker linked to proliferation. Haematologica  2020,105(3),774-783","journal-title":"Haematologica"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1136\/gutjnl-2014-308932","volume":"65","author":"Wang S.M.","year":"2016","unstructured":"Wang S.M.; Tie J.; Wang W.L.; Hu S.J.; Yin J.P.; Yi X.F.; Tian Z.H.; Zhang X.Y.; Li M.B.; Li Z.S.; Nie Y.Z.; Wu K.C.; Fan D.M.; POU2F2-oriented network promotes human gastric cancer metastasis. Gut  2016,65(9),1427-1438","journal-title":"Gut"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.18632\/oncotarget.1497","volume":"4","author":"Abdi J.","year":"2013","unstructured":"Abdi J.; Chen G.; Chang H.; Drug resistance in multiple myeloma: Latest findings and new concepts on molecular mechanisms. Oncotarget  2013,4(12),2186-2207","journal-title":"Oncotarget"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"5005","DOI":"10.3390\/ijms23095005","volume":"23","author":"Koo N.","year":"2022","unstructured":"Koo N.; Sharma A.K.; Narayan S.; Therapeutics targeting p53-MDM2 interaction to induce cancer cell death. Int J Mol Sci  2022,23(9),5005","journal-title":"Int J Mol Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"4081","DOI":"10.1007\/s13277-013-0999-1","volume":"34","author":"Heese K.","year":"2013","unstructured":"Heese K.; The protein p17 signaling pathways in cancer. Tumour Biol  2013,34(6),4081-4087","journal-title":"Tumour Biol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/s41408-023-00919-2","volume":"13","author":"Liu E.","year":"2023","unstructured":"Liu E.; Sudha P.; Becker N.; Jaouadi O.; Suvannasankha A.; Lee K.; Abonour R.; Abu Zaid M.; Walker B.A.; Identifying novel mechanisms of biallelic TP53 loss refines poor outcome for patients with multiple myeloma. Blood Cancer J  2023,13(1),144","journal-title":"Blood Cancer J"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"107041","DOI":"10.1016\/j.leukres.2023.107041","volume":"127","author":"Wang Q.","year":"2023","unstructured":"Wang Q.; Shi Q.; Chen Y.; Wang G.; Shen L.; Recombinant human p53 adenovirus injection combined with Bortezomib inhibits proliferation and promotes apoptosis in multiple myeloma. Leuk Res  2023,127,107041","journal-title":"Leuk Res"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"3551","DOI":"10.1182\/bloodadvances.2022009387","volume":"7","author":"Chang Y.T.","year":"2023","unstructured":"Chang Y.T.; Chiu I.; Wang Q.; Bustamante J.; Jiang W.; Rycaj K.; Yi S.; Li J.; Kowalski-Muegge J.; Matsui W.; Loss of p 53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cells. Blood Adv  2023,7(14),3551-3560","journal-title":"Blood Adv"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"eadg7940","DOI":"10.1126\/sciadv.adg7940","volume":"9","author":"Clifton L.A.","year":"2023","unstructured":"Clifton L.A.; Wacklin-Knecht H.P.; \u00c5d\u00e9n J.; Mushtaq A.U.; Sparrman T.; Gr\u00f6bner G.; Creation of distinctive Bax-lipid complexes at mitochondrial membrane surfaces drives pore formation to initiate apoptosis. Sci Adv  2023,9(22),eadg7940","journal-title":"Sci Adv"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.rvsc.2016.02.004","volume":"105","author":"Dolka I.","year":"2016","unstructured":"Dolka I.; Kr\u00f3l M.; Sapierzy\u0144ski R.; Evaluation of apoptosis-associated protein (Bcl-2, Bax, cleaved caspase-3 and p53) expression in canine mammary tumors: An immunohistochemical and prognostic study. Res Vet Sci  2016,105,124-133","journal-title":"Res Vet Sci"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"8155","DOI":"10.18632\/aging.202625","volume":"13","author":"Yu Y.","year":"2021","unstructured":"Yu Y.; Wang Z.; Zheng Q.; Li J.; FAM72 serves as a biomarker of poor prognosis in human lung adenocarcinoma. Aging  2021,13(6),8155-8176","journal-title":"Aging"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/ijms24010375","volume":"24","author":"Bai Y.","year":"2022","unstructured":"Bai Y.; Cao K.; Zhang P.; Ma J.; Zhu J.; Prognostic and immunological implications of FAM72A in pan-cancer and functional validations. Int J Mol Sci  2022,24(1),375","journal-title":"Int J Mol Sci"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010311258240729080309","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/232787\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010311258240729080309","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T10:51:27Z","timestamp":1738234287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/232787\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892010311258240729080309","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2024-02-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-17","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}